Evidence map›Paper›PMID 21483689›Full record

ArticlePloS one2011

R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodes.

Michael Santosuosso, Elda Righi, E David Hill, Pierre R Leblanc, Brett Kodish, Hari N Mylvaganam, Nagadenahalli B Siddappa, Liljana Stevceva, Shiu-Lok Hu, Musie Ghebremichael and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. HIV-1 envelope proteins up-regulateThe Journal of biological chemistry · 2019
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. T-Cell Signaling in HIV-1 Infection.The open virology journal · 2013
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Michael SantosuossoInfectious Diseases Medicine Division, Vaccine and Immunotherapy Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.
Elda Righi
E David Hill
Pierre R Leblanc
Brett Kodish
Hari N Mylvaganam
Nagadenahalli B Siddappa
Liljana Stevceva
Shiu-Lok Hu
Musie Ghebremichael
Agnes-L Chenine
Avi-Hai Hovav
Ruth M Ruprecht
Mark C Poznansky
Massachusetts General Hospital · USDana-Farber Cancer Institute · USHarvard University Press · USHebrew University of Jerusalem · ILUniversity of Washington · US

Funding

YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localizationR01AI049757 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI POZNANSKY, MARK COLEMAN · 2001 to 2010
$4.0M
SHIV Transmission Through Oral Versus Other MucosaeR01DE016013 · NIDCR · DANA-FARBER CANCER INSTITUTE · PI RUPRECHT, RUTH MARGRIT · 2004 to 2007
$2.6M
CIHRNCRR NIH HHS P51 RR000165NCRR NIH HHS RR00165NIAID NIH HHS P01 AI048240NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI049757NIAID NIH HHS R01 AI49757NIDCR NIH HHS R01 DE016013
6 · The paper itself

Abstract

backgroundHIV-1 is a pathogen that T cell responses fail to control. HIV-1gp120 is the surface viral envelope glycoprotein that interacts with CD4 T cells and mediates entry. HIV-1gp120 has been implicated in immune dysregulatory functions that may limit anti-HIV antigen-specific T cell responses. We hypothesized that in the context of early SHIV infection, immune dysregulation of antigen-specific T-effector cell and regulatory functions would be detectable and that these would be associated or correlated with measurable concentrations of HIV-1gp120 in lymphoid tissues.

methodsRhesus macaques were intravaginally inoculated with a Clade C CCR5-tropic simian-human immunodeficiency virus, SHIV-1157ipd3N4. HIV-1gp120 levels, antigen-specificity, levels of apoptosis/anergy and frequency and function of Tregs were examined in lymph node and blood derived T cells at 5 and 12 weeks post inoculation. RESULTS/

conclusionsWe observed reduced responses to Gag in CD4 and gp120 in CD8 lymph node-derived T cells compared to the peripheral blood at 5 weeks post-inoculation. Reduced antigen-specific responses were associated with higher levels of PD-1 on lymph node-derived CD4 T cells as compared to peripheral blood and uninfected lymph node-derived CD4 T cells. Lymph nodes contained increased numbers of Tregs as compared to peripheral blood, which positively correlated with gp120 levels; T regulatory cell depletion restored CD8 T cell responses to Gag but not to gp120. HIV gp120 was also able to induce T regulatory cell chemotaxis in a dose-dependent, CCR5-mediated manner. These studies contribute to our broader understanding of the ways in which HIV-1 dysregulates T cell function and localization during early infection.

Indexed as

AnimalsAntibody SpecificityAntigens, CDCell DeathChemotaxisGene Products, gagHIV Envelope Protein gp120HumansLymph NodesMacaca mulattaMucous MembraneReceptors, CCR5Receptors, G-Protein-CoupledSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTime FactorsAntigens, CDGene Products, gaggp120 protein, Human immunodeficiency virus 1HIV Envelope Protein gp120Receptors, CCR5Receptors, G-Protein-Coupled

Identifiers

PMID21483689
PMCPMC3071731
OpenAlexW2114809100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.